PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris – ticker code BIO), today announced that it has entered into an exclusive licensing agreement with Immtech Pharmaceuticals Inc. (AMEX: IMM) covering the European commercialization rights to pafuramidine maleate.
